A modern study suggests a rapid diagnostic tool, guided by a specific biomarker, could improve sepsis outcomes by reducing mortality rates without delaying antibiotic treatment.
Sepsis, a life-threatening condition triggered by the body’s overwhelming response to infection, affects thousands annually and requires swift diagnosis and treatment. In England alone, sepsis is linked to approximately 48,000 deaths each year.
Diagnosing sepsis can be challenging, as its early symptoms often mimic those of other illnesses, and a definitive diagnostic test has been lacking. This uncertainty can lead to both overdiagnosis and underdiagnosis, impacting patient care.
Delayed treatment can have severe consequences. Whereas antibiotics are crucial for confirmed sepsis cases, unnecessary antibiotic utilize contributes to the growing problem of antimicrobial resistance. Conversely, a missed or delayed diagnosis can prolong suffering and worsen outcomes.
Researchers from the University of Liverpool and the Center for Trials Research at Cardiff University evaluated the effectiveness of a rapid test designed for early sepsis detection.
Published on Sunday in The Lancet Respiratory Medicine, the study focused on an algorithm guided by procalcitonin levels.
Procalcitonin is a biomarker that rises in response to bacterial infections and can help clinicians determine whether to administer antibiotics. Despite previous inconclusive research, the team conducted a large-scale, controlled study to assess its utility in emergency settings.
The study included 7,667 patients who presented to emergency departments with suspected sepsis.
Researchers aimed to determine if incorporating the rapid test into standard medical practice could improve diagnostic accuracy, reduce inappropriate antibiotic use, and maintain patient safety, as measured by overall mortality.
The results showed a 17% relative reduction in mortality, from 16.6% to 13.6%, suggesting that approximately 31 lives could be saved for every 1,000 patients treated for suspected sepsis. This finding highlights the potential for improved outcomes with more accurate and timely diagnosis.
The benefit was even more pronounced among patients from disadvantaged communities, a finding that underscores the importance of addressing health inequities in sepsis care.
Interestingly, the study found that using the procalcitonin-based algorithm did not affect the speed of administering intravenous antibiotics. This result contradicted the researchers’ initial hypothesis and is a significant finding, as rapid antibiotic initiation has been a primary goal of sepsis treatment protocols.
Researchers had anticipated the test would lead to faster antibiotic administration, but the study demonstrated that the time to initiate treatment remained consistent regardless of whether clinicians used the tool. This suggests the biomarker’s benefit lies in more informed decision-making, rather than simply accelerating treatment.
The authors concluded that the results support the use of rapid tests for early sepsis detection and emphasize the need for continued development of biomarkers and clinical decision support tools. These tools can empower clinicians to make more informed treatment choices.
Sepsis remains a leading cause of death worldwide, but advancements in diagnostic tools offer hope for reducing its impact. This study provides valuable data for implementing these tools in clinical practice and opens avenues for future research. Integrating these methods into healthcare systems will require further investigation into their mechanisms of action, economic evaluations, and the development of robust implementation models.
The study was conducted by teams from the University of Liverpool and NHS University Hospitals of Liverpool Group, in collaboration with specialists from 20 emergency hospitals across England and Wales.
